DAX-0,15 % EUR/USD-0,24 % Gold-0,60 % Öl (Brent)+2,95 %

Abgenix; Kooperationen des Marktführers im Bereich Antikörper - 500 Beiträge pro Seite


AnzeigeAdvertisement

Beitrag schreiben

Begriffe und/oder Benutzer

 

Da sich die neuen Kooperationen bei Abgenix häufen (im Schnitt jeden Monat eine) möchte ich insbesondere unsere Medarex- und Morphosysanhänger auf den Marktführer hinweisen ;) !

Heute ist folgende Zusammenarbeit angekündigt worden:

CAMBRIDGE, Mass. and FREMONT, Calif., Sept. 6 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN) and Abgenix, Inc. (Nasdaq: ABGX) today announced a collaboration providing Abgenix with access to ImmunoGen`s maytansinoid Tumor-Activated Prodrug (TAP) technology for use with Abgenix`s fully human antibodies generated with XenoMouse(TM) technology. ImmunoGen will receive $5 million in technology access fee payments, as well as potential milestone payments, and royalties on net sales of any resulting products. In addition, Abgenix will purchase $15 million of ImmunoGen common stock at $19.00 per share.

The multi-year agreement provides Abgenix with a broad license to utilize ImmunoGen`s maytansinoid TAP platform in its antibody product research efforts and an option to obtain product licenses for a large number of antigen targets over the agreement`s ten-year term. Abgenix will be responsible for manufacturing, product development and marketing of any products developed through the collaboration. ImmunoGen may produce preclinical and clinical material, at Abgenix`s request, for a manufacturing payment.

"Having access to ImmunoGen`s existing TAP technology will allow Abgenix to extend its product reach, particularly in the oncology field," said R. Scott Greer, chairman and CEO of Abgenix. "Many of the targets emerging from our antigen sourcing collaborations may be appropriate for tumor-activated prodrug therapy. The alliance represents another example of how Abgenix is assembling the technologies necessary to rapidly move from a genomics target to an effective therapeutic product."

"We are pleased to welcome Abgenix, a leader in producing fully human monoclonal antibodies, as one of our partners," said Mitchel Sayare, Ph.D., Chairman and CEO of ImmunoGen, Inc. "In addition to Abgenix`s XenoMouse technology, this collaboration also leverages Abgenix`s numerous genomics partners who will provide access to targets. This agreement is an important step toward our goal of exploiting new genomics information through development of new antibody-based TAP products."

ImmunoGen`s tumor-activated prodrug technology consists of potent cytotoxic drugs coupled to monoclonal antibodies that recognize and bind to tumor cells, effectively delivering the cytotoxic agents directly to cancer cells. Maytansinoids are a family of potent chemotherapeutic agents a thousand-fold more cytotoxic than existing chemotherapeutic drugs. In animal studies, maytansinoid TAPs eradicated human tumor xenografts. TAPS using ImmunoGen`s technology have the potential to be more potent and less toxic to the patient than existing chemotherapeutics.

ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for cancer treatment. The Company has created potent tumor-activated prodrugs, consisting of drugs coupled to monoclonal antibodies for delivery to and destruction of cancer cells. The most advanced TAP, huC242-DM1/SB-408075, designed to treat colorectal and pancreatic cancer, is in a Phase I/II human clinical study. In addition to its maytansinoid platform of TAPs, the Company is working on other proprietary TAP platforms comprising agents, such as taxanes, which exert cell-killing activity via different mechanisms of action.

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer. For more information on Abgenix, visit the company`s Web site at www.abgenix.com.

Abgenix developed XenoMouse(TM) technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical, genomics and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer.

This press release includes forward-looking statements based on management`s current expectations. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the ability to secure future funding; the success of ImmunoGen`s research strategy; the applicability of the discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; delayed achievements of milestones; reliance on collaborators; uncertainty as to whether ImmunoGen`s potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from the government, private healthcare insurers and third-party payors; and the uncertainties as to the extent of future government regulation of the pharmaceutical business.

Statements made in this press release about Abgenix`s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.

Hier die Übersicht der bisherigen Kooperationen auf der Homepage von Abgenix:

http://www.abgenix.com/forms/Collaborations.asp

Gruß Bogo!
Abgenix wird am Montag bei der Investmentbank Stephens auf der heute beginenden Konferenz für Antikrebsmittel vorgestellt (8.00 Uhr).

Gruß Bogo!


P.S. Cell Genesys am Dienstag um 10.00 Uhr.
Hi Bogo,
woher hast Du die Infos über die Konferenz und den Zeitplan?
Danke,
ml
Nochmals Danke Bogo!
Sehr interessante Seite. Bin mal gespannt, was dort so an Neuigkeiten rauskommt und wie das auf die Kurse
wirkt. Ist ja die halbe Branche vertreten!
Hat zwar nicht direkt mit Abgenix zu tun, aber da Abgenix ja scheinbar Anteile an IMGN erwerben will doch ganz interessant:

CAMBRIDGE, Mass. and MUNICH, Germany, Oct. 2 /PRNewswire/ -- MorphoSys AG (Neuer Markt: MOR), the German biotechnology company based in Munich/Martinsried, today announced a collaboration with ImmunoGen, Inc. (Nasdaq: IMGN), a Cambridge, Massachusetts-based biotechnology company. The two companies will collaborate on the development of human antibodies for the treatment of cancer. Under the agreement, MorphoSys will receive a technology access payment, as well as development-related milestone payments and royalties on marketed products. Financial details were not disclosed.

In the collaboration, MorphoSys will apply its HuCAL-Fab technology to discover and optimize fully human antibodies against an unspecified ImmunoGen cell surface target associated with a number of forms of cancer. ImmunoGen will be responsible for developing one or more antibodies generated by MorphoSys into a marketable product.

"We are delighted to be collaborating with ImmunoGen, a company with great experience in the development of antibody-based cancer therapeutics," commented Daniel L. Menichella, President, MorphoSys USA and Senior Vice President of Corporate Development. "This deal, our sixth this year, is another example of our ability to form partnerships based on our HuCAL technology with companies committed to developing fully human antibodies."

"We look forward to working with MorphoSys in this program. We believe their antibody library is the best technology available for rapid generation of human antibodies to our target," said Walter A. Blattler, Ph.D., Executive Vice President, Science and Technology, ImmunoGen. "This program is a part of our strategy of developing antibody-based products from targets generated by our Apoptosis Technology, Inc. subsidiary, and is an example of our efforts to fill our pipeline of internally-developed products."

MorphoSys develops and applies innovative technologies for the production of synthetic antibodies which accelerate drug discovery and target characterisation. Founded in 1992, the Company`s proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers world-wide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Roche AG (Basel/Switzerland), DuPont Pharmaceuticals (Wilmington, Delaware/USA), Millennium (Cambridge, Mass/USA), Chiron (Emeryville, California/USA), GPC Biotech AG (Munich/Germany) ProChon Biotech (Revohot/Israel) and Eos Biotechnology (South San Francisco/California/USA).

ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for cancer treatment. The Company creates potent tumor-activated prodrugs (TAPs), consisting of small molecular, cytotoxic drugs coupled to monoclonal antibodies for delivery to and destruction of cancer cells. The most advanced TAP, huC242-DM1/SB-408075, designed to treat colorectal and pancreatic cancer, is in two Phase I/II human clinical studies. The Company`s subsidiary, Apoptosis Technology, Inc. (ATI), identifies defects in apoptosis - also known as cell suicide -- pathways. Besides MorphoSys, the company has collaborations with SmithKline Beecham, Genentech, Abgenix and British Biotech.

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The companies caution readers that forward-looking statements, including without limitation those relating to the companies` future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the companies` proprietary rights, uncertainties related to operations and other factors described in the Offering Circular of MorphoSys dated March 5, 1999 relating to the company`s public offering. The companies are not undertaking any obligation to release publicly any updates to any forward- looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

This press release includes forward-looking statements based on management`s current expectations. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the ability to secure future funding; the success of ImmunoGen`s research strategy; the applicability of the discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; delayed achievements of milestones; reliance on collaborators; uncertainty as to whether ImmunoGen`s potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from the government, private healthcare insurers and third-party payors; and the uncertainties as to the extent of future government regulation of the pharmaceutical business.

Gruß Bogo!

P.S Falls es in D noch Abgenix-Aktionäre geben sollte würde ich gerne mal ne Meinung hören!!!!!
Nach Börsenschluß:

FREMONT, Calif., Oct. 2 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX) today announced the filing of an Investigational New Drug (IND) application to the FDA by Pfizer for a fully human monoclonal antibody product candidate for the treatment of cancer, which was generated with Abgenix`s XenoMouse(TM) technology. This milestone triggers an undisclosed payment to Abgenix.

"We are pleased with the progress of our research alliance with Pfizer which has resulted in the first antibody generated under a XenoMouse technology collaboration to enter the clinic," said R. Scott Greer, chairman and CEO of Abgenix. "This becomes the third XenoMouse antibody in human clinical trials, including two of our own. Through our collaborations and internal efforts, we believe the XenoMouse platform will continue to provide new and important antibody therapies for various disease indications."

Abgenix`s research alliance with Pfizer began in December 1997 to provide Pfizer a license to XenoMouse technology for the generation of fully human antibodies to Pfizer`s antigen targets. As part of this arrangement, Pfizer made an equity investment in Abgenix. The research collaboration has been expanded several times to include currently up to five antibody product candidates named by Pfizer. Pfizer will be responsible for product development, manufacturing and marketing of any products developed through the collaboration. Abgenix will receive license fees, milestone payments plus royalties on product sales.

Abgenix is a biopharmaceutical company focused on the development and commercialization of antibody therapies for a variety of diseases. The company developed XenoMouse(TM) technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix uses its XenoMouse technology to build a large and diversified product portfolio through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies and through the development of its own internal proprietary products. For more information on Abgenix, visit the company`s web site at www.abgenix.com.

Statements made in this press release about Abgenix`s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix`s patent portfolio. Please see Abgenix`s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.

Gruß Bogo!
Zwar schon etwas her, aber dafür in Deutsch:
11.10.2000
Abgenix kaufen
Robertson Stephens

Jay Silverman, für die biopharmazeutische Industrie verantwortlicher Analyst bei Robertson Stephens, hat sein Empfehlung für Abgenix (WKN 915298) als Strong Buy wiederholt.

Abgenix verwende Mäuse, um Antikörper gegen Entzündungen, Immundefekte, Krebs und transplantationsbedingte Probleme zu erzeugen. Das Unternehmen habe bekanntgegeben, daß Pfitzer einen mit Hilfe von XenoMäusen getesteten, monoklonalen Antikörper zur Behandlung von Krebs bei der Gesundheitsbehörde als in Testung befindliches Medikament gemeldet hat. So wie bei den anderen XenoMaus-Partnerschaften, sei Pfitzer zur Gänze für die Produktentwicklung, die Erzeugung und das Marketing verantwortlich. Abgenix werde in Falle der Marktreife Lizenzgebühren, Abschlagszahlungen und Umsatzprovisionen erhalten.

Dieses lang erwartete Ereignis bedeute die erste Testanmeldung eines Medikamentes aus einer Xeno:aus-Partnerschaft. Die Antikörper von Pfitzer seien nach den von Abgenix selbst angemeldeten Produkten ABX-IL8 und ABX-EGF die dritten zur Gänze menschlichen XenoMaus-Antikörper, die an Menschen getestet werden. Auf Basis der ungefähr 20 XenoMaus-Partnerschaften werden in den nächsten Jahren noch viele zusätzliche Testanmeldungen erwartet.

Auf Grund der Tatsache, daß die XenoMaus-Vereinbarungen langsam Testmedikamente hervorbringen, und daß auch die übrige Produktentwicklung von Abgenix gut voranschreitet, scheine es nach wie vor so, daß Abgenix sich als führendes Unternehmen auf dem Gebiet der Antikörperforschung etablieren werde. Deshalb die Strong Buy Empfehlung.

Gruß Bogo!


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.